Ivko T I
Summary The pharmacoeconomic study on the medicine regimens of diabetes mellitus (DM) type 2 was conducted with the purpose of their improvement. The research was based on the retrospective analysis of 599 medical histories of patients of type 2 diabetes. These patients were treated at the Vinnytsia Regional Clinical Endocrinology Clinic in 2011-2012. The studies of medicine regimens were performed by the «cost-effectiveness» analysis. We have found that the scheme of pharmacotherapy metformin+gliclazide has cost-effective advantage over the scheme pharmacotherapy metformin+glimepiride.
Summary The pharmacoeconomic study on the medicine regimens of diabetes mellitus (DM) type 2 was conducted with the purpose of their improvement. The research was based on the retrospective analysis of 599 medical histories of patients of type 2 diabetes. These patients were treated at the Vinnytsia Regional Clinical Endocrinology Clinic in 2011-2012. The studies of medicine regimens were performed by the «cost-effectiveness» analysis. We have found that the scheme of pharmacotherapy metformin+gliclazide has cost-effective advantage over the scheme pharmacotherapy metformin+glimepiride.
